HIV peripheral neuropathy progression: Protection with glucose-lowering drugs?

Scott R. Evans, Anthony J. Lee, Ronald J. Ellis, Huichao Chen, Kunling Wu, Ronald J. Bosch, David B. Clifford

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


The purpose of this study is to evaluate risk factors for progression from asymptomatic peripheral neuropathy (APN) to symptomatic peripheral neuropathy (SPN). Antiretroviral therapy (ART)-naïve patients initiating combination ART were followed longitudinally and screened for signs/symptoms of PN. Having APN was associated with higher odds of future SPN (odds ratio (OR)=1.58, 95 % confidence interval (CI)=(1.08, 2.29), p=0.027). Neurotoxic ART use was associated with increased odds of progression to SPN (OR= 2.16, 95 % CI=(1.21, 3.85), p=0.009) while use of glucoselowering drugs (non-insulin) was protective (OR=0.12, 95 % CI=(0.02, 0.83), p=0.031). Use of glucose-lowering drugs (non-insulin) may prevent progression from APN to SPN.

Original languageEnglish
Pages (from-to)428-433
Number of pages6
JournalJournal of NeuroVirology
Issue number5
StatePublished - Oct 2012


  • Glucose-lowering drugs
  • HIV
  • Peripheral neuropathy
  • Risk factors
  • Symptomatic peripheral neuropathy


Dive into the research topics of 'HIV peripheral neuropathy progression: Protection with glucose-lowering drugs?'. Together they form a unique fingerprint.

Cite this